Chemotherapy Treatment Plan Note (Pediatric Oncology)

Patient: [name, MRN, DOB]

Guardian(s) Present: [name(s) and relationship]

Interpreter: [language] (Omit if not used)

Author/Service: [name, role; Pediatric Hematology/Oncology]

Attending of Record: [name]

Protocol/Regimen: [protocol name, number, phase/arm/stratum as applicable]

Planned Start Date/Setting: [date; inpatient / outpatient] (Include brief rationale if inpatient)

Clinical Summary

[Narrative clinical summary] (Write 4–8 sentences covering: diagnosis with key pathology and molecular features; current disease status; treatment context and rationale for regimen selection; explicit treatment intent [curative / disease control / bridge to transplant / palliation]; planned start date and setting. Do not infer details not documented.)

Diagnosis and Staging

Pathologic Confirmation: [diagnosis, specimen source, pathology report date]

Stage/Risk Group: [staging system, risk stratification, CNS/sanctuary site involvement; date of staging]

Current Disease Status: [remission status, MRD result if applicable, measurable disease sites]

Key Baseline Markers: [LDH, blast percentage, other disease burden markers as relevant]

(If staging or risk stratification is pending, document what is pending, expected date, and whether regimen is provisional.)

Pre-Treatment Readiness

Anthropometrics: Height [cm], Weight [kg], BSA [m²], date measured; [actual / adjusted] dosing weight; [recalculation triggers]

Organ Function: [renal function with date; hepatic function with date; performance status; significant comorbidities affecting regimen]

Allergies/Prior Reactions: [drug allergies with reaction type; prior chemotherapy hypersensitivity reactions] (State NKDA if none)

Baseline Evaluations: (Use status tags: Completed [date] / Ordered / Pending / Not indicated. Mark Pending items as start-contingent or not.)

• Labs: [CBC, CMP, Mg/Phos, uric acid, LDH, coagulation studies, pregnancy test if applicable]
• Cardiac evaluation: [test type and result] (Include if cardiotoxic agents planned)
• Audiology: [test type and result] (Include if ototoxic agents planned)
• Other protocol-required evaluations: [test and status]

Central Access: [line type, placement status, functionality] (Include LP/IT therapy sedation plan if applicable)

Regimen Plan

Agent (generic name)	Dose (mg/m² or mg/kg AND calculated mg)	Route	Schedule (cycle/day, frequency)	Duration/Rate	Sequence Constraints	Premeds/Rescue
[agent]	[dose per unit AND calculated dose]	[route]	[cycle, day, frequency]	[duration or rate]	[timing or sequence constraints]	[premedications, rescue agents]

(Add one row per agent. Use safe decimal conventions: leading zeros for values less than 1, no trailing zeros.)

Number of Planned Cycles: [number, cycle length, order time limitation if applicable]

Dose Calculation Basis: BSA [m²] / Weight [kg] measured [date]; recalculation policy: [triggers for dose update]

Criteria to Treat/Hold/Modify:

• ANC minimum: [threshold and action if below]
• Platelet minimum: [threshold and transfusion considerations]
• Renal function: [cutoff and dose adjustment]
• Hepatic function: [cutoff and dose adjustment]
• Infection/fever: [constraints and required workup]
• Toxicity modifications: [regimen-specific rules for dose reduction or delay]

(If clinical trial: reference protocol number; protocol documents remain source of truth.)

Supportive Care and Monitoring

Antiemetic Plan: [regimen based on emetogenic risk; rescue agents; home PRN plan]

TLS Prophylaxis: [low / intermediate / high] risk; [hydration plan; allopurinol/rasburicase; lab monitoring frequency; ICU triggers if applicable]

Antimicrobial Prophylaxis: PJP: [agent, schedule]; Antifungal: [agent if indicated]; Antiviral: [agent if indicated]

Growth Factor: [agent and timing] (State "not indicated" if not planned)

Other Supportive Care: [bowel regimen; mucositis prevention; transfusion thresholds; special blood product requirements]

Monitoring Schedule:

• Prior to Day 1: [required labs, baseline assessments, verification checks]
• During cycle: [lab frequency, drug-specific monitoring, toxicity surveillance]
• Between cycles: [response assessment timing: imaging, marrow, MRD; criteria to proceed]

Escalation Instructions: Fever threshold [temperature]; [emergency contact pathway; ED criteria per institutional policy]

Consent, Education, and Fertility

Parental Permission: [Documented] [date, time, participants]

Patient Assent: [Obtained / Not developmentally appropriate—document rationale]

Education Provided: [Topics covered: diagnosis, treatment goals, schedule, drug names, adverse effects, urgent symptoms, home handling, follow-up] (Document interpreter use, comprehension assessment method, and learning barriers identified.)

Fertility Preservation: [Discussed / Referral made / Declined / Not applicable—document rationale; pregnancy avoidance counseling if relevant]

Plan Summary

• [Ready to start / Pending prerequisites with expected completion]
• [Confirmed start date and location]
• [Key prophylaxis: TLS plan, PJP agent, antiemetic regimen]
• [Next follow-up date and monitoring milestones]

Attestation: [Attending signature and date]

(Omit sections or fields not applicable rather than inserting N/A, except safety-critical items which must be marked Pending with plan. Do not infer staging, consent status, or baseline results—confirm data source or mark pending.)